Tenofovir exalidex - ContraVir Pharmaceuticals

Drug Profile

Tenofovir exalidex - ContraVir Pharmaceuticals

Alternative Names: CMX-157; HDP-Tenofovir; Hexadecyloxypropyl-tenofovir; lipid conjugate TFV(tenofovir); Lipid conjugate YTFV; TXL™

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chimerix
  • Developer Chimerix; ContraVir Pharmaceuticals
  • Class Antiretrovirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis B
  • Suspended HIV infections

Most Recent Events

  • 17 Oct 2017 ContraVir Pharmaceuticals enters into collaboration with the Li Ka Shing Institute of Virology at University of Alberta to evaluate tenofocir exalidex for Hepatitis B treatment
  • 11 Sep 2017 ContraVir Pharmaceuticals plans a phase I clinical trial for Renal impairment in September 2017
  • 11 Sep 2017 The US FDA approves IND application for tenofovir exalidex in Hepatitis B
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top